Edmond, OK, United States of America

Martin Turman

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: University of Oklahoma. Active years: 2009.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Martin Turman: Innovator in Disease Treatment

Introduction

Martin Turman is a notable inventor based in Edmond, OK (US). He has made significant contributions to the field of medical treatments through his innovative research and development of flexible heteroarotinoids. His work focuses on addressing various disease conditions that affect human health.

Latest Patents

Martin Turman holds a patent for his invention titled "Treatment and inhibition of disease conditions using flexible heteroarotinoids." This patent outlines methods for treating, reducing, inhibiting, or preventing several diseases through the administration of flexible heteroarotinoids. The diseases that can benefit from this treatment include cancers, diabetes, hemophilia, liver disease, and several others related to abnormal differentiation and metabolism.

Career Highlights

Turman is affiliated with the University of Oklahoma, where he continues to engage in groundbreaking research. His work has the potential to impact a wide range of medical conditions, making him a valuable asset to the scientific community.

Collaborations

Some of his notable coworkers include Doris Manglaracina Benbrook and Suresh Guruswamy. Their collaborative efforts contribute to the advancement of research in the field of disease treatment.

Conclusion

Martin Turman's innovative work in the treatment of various diseases through flexible heteroarotinoids showcases his dedication to improving human health. His contributions are significant and reflect the importance of research in developing effective medical solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…